West Roxbury, MA, United States of America

Michaela Lerner


 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Michaela Lerner: Innovator in Anti-VLA-4 Related Assays

Introduction

Michaela Lerner is a prominent inventor based in West Roxbury, MA (US). She has made significant contributions to the field of biomedical research, particularly in the development of assays related to VLA-4. With a total of five patents to her name, Michaela has established herself as a key figure in her area of expertise.

Latest Patents

Michaela's latest patents focus on anti-VLA-4 related assays. These patents disclose methods and apparatus for assaying the level of analytes in a sample related to VLA-4. One of the methods described involves decreasing the level of an anti-integrin antibody in a subject. This process includes contacting a biological sample from a subject with a detectable capture agent associated with a substrate, which can bind an anti-integrin antibody in the sample. The method further involves detecting the binding of the capture agent with the level of the anti-integrin antibody and treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level.

Career Highlights

Michaela Lerner is currently employed at Biogen MA Inc., where she continues to innovate and contribute to the field of biomedical research. Her work has been instrumental in advancing the understanding and treatment of conditions related to VLA-4.

Collaborations

Michaela collaborates with notable colleagues, including Tatiana Plavina and Paula S Hochman. These partnerships enhance the research and development efforts within her team.

Conclusion

Michaela Lerner's contributions to the field of anti-VLA-4 related assays highlight her innovative spirit and dedication to advancing biomedical research. Her work continues to impact the scientific community and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…